HRP20210243T1 - Hiperbulirajući sojevi bakterije shigella - Google Patents
Hiperbulirajući sojevi bakterije shigella Download PDFInfo
- Publication number
- HRP20210243T1 HRP20210243T1 HRP20210243TT HRP20210243T HRP20210243T1 HR P20210243 T1 HRP20210243 T1 HR P20210243T1 HR P20210243T T HRP20210243T T HR P20210243TT HR P20210243 T HRP20210243 T HR P20210243T HR P20210243 T1 HRP20210243 T1 HR P20210243T1
- Authority
- HR
- Croatia
- Prior art keywords
- shigella
- strain
- bacterium
- bullae
- bacteria
- Prior art date
Links
- 241000607768 Shigella Species 0.000 title claims 20
- 241000894006 Bacteria Species 0.000 claims 9
- 208000002352 blister Diseases 0.000 claims 8
- 238000000034 method Methods 0.000 claims 5
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 239000001963 growth medium Substances 0.000 claims 3
- 239000002609 medium Substances 0.000 claims 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 101100451792 Bacillus subtilis (strain 168) htrB gene Proteins 0.000 claims 1
- 241000350158 Prioria balsamifera Species 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 239000000706 filtrate Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 229920006008 lipopolysaccharide Polymers 0.000 claims 1
- 101150011311 lpxL gene Proteins 0.000 claims 1
- 101150081449 stxA gene Proteins 0.000 claims 1
- 101150017169 stxB gene Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0283—Shigella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (16)
1. Soj bakterije Shigella koji ne eksprimira funkcionalan enzim HtrB, naznačen time što soj bakterije Shigella eksprimira najviše 4 od proteina TolA, TolB, TolQ, TolR i Pal.
2. Soj bakterije Shigella u skladu s patentnim zahtjevom 1, naznačen time što je htrB izbačen.
3. Soj bakterije Shigella u skladu s patentnim zahtjevom 1 ili 2, naznačen time što ne eksprimira protein TolR.
4. Soj bakterije Shigella u skladu s patentnim zahtjevom 2 ili 3, naznačen time što bakterija eksprimira 4 od proteina, no ne i TolR.
5. Soj bakterije Shigella u skladu s bilo kojim od patentnim zahtjevima 1-4, naznačen time što je soj ΔtolR bakterije Shigella.
6. Soj bakterije Shigella u skladu s bilo kojim od patentnim zahtjevima 1-5, naznačen time što bakterija ne eksprimira nativni Shigella lipopolisaharid.
7. Soj bakterije Shigella u skladu s patentnim zahtjevom 6, naznačen time što bakterija ne eksprimira nativni Shigella antigen O.
8. Soj bakterije Shigella u skladu s patentnim zahtjevom 1-7, naznačen time što je soj soj ΔtolRΔgalU.
9. Soj bakterije Shigella u skladu s bilo kojim od patentnim zahtjevima 1-8, naznačen time što je gen stxA i/ili gen stxB inaktiviran.
10. Postupak priprave bula iz bakterije Shigella, naznačen time što se sastoji u koraku izdvajanja bula iz medija za uzgoj koji sadrži bakteriju iz roda Shigella koja ne eksprimira funkcionalan enzim HtrB, koju se uzgaja u uvjetima koji omogućuju otpuštanje bula iz bakterija u medij.
11. Postupak u skladu s patentnim zahtjevom 10, naznačen time što se bakterije uzgaja u uvjetima s ograničenom količinom željeza.
12. Bula, naznačena time što je izolirana bula ili bula koju se može dobiti iz bakterije Shigella koja ne eksprimira funkcionalan enzim HtrB.
13. Pripravak, naznačen time što sadrži bule koje se, tijekom uzgoja soja bakterije Shigella u skladu s bilo kojim od patentnim zahtjevima 1 do 9 ili kojeg se može dobiti postupkom u skladu s patentnim zahtjevom 10 ili 11, otpušta u medij za uzgoj.
14. Pripravak u skladu s patentnim zahtjevom 13, naznačen time što ne sadrži žive i/ili cijele bakterije.
15. Pripravak, naznačen time što sadrži bule, gdje se bule može dobiti postupkom u skladu s patentnim zahtjevima 10 ili 11, ili gdje su bule prisutne u filtratu kojeg se može dobiti filtriranjem kroz 0,22 mikrometarski filtar medija za uzgoj u kojem je uzgajan soj bakterije Shigella u skladu s bilo kojim od patentnim zahtjevima 1 do 9.
16. Medij za uzgoj koji sadrži soj bakterije Shigella u skladu s patentnim zahtjevima 1 do 9, ili kojeg se može dobiti postupkom u skladu s patentnim zahtjevom 10, naznačen time što se bakterije uzgaja u uvjetima koji omogućuju otpuštanje bula iz bakterija u medij.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0917002.8A GB0917002D0 (en) | 2009-09-28 | 2009-09-28 | Improved shigella blebs |
| EP17168855.9A EP3279313B1 (en) | 2009-09-28 | 2010-09-28 | Hyperblebbing shigella strains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210243T1 true HRP20210243T1 (hr) | 2021-04-02 |
Family
ID=41350492
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170845TT HRP20170845T1 (hr) | 2009-09-28 | 2017-06-02 | Hiperbulirajući sojevi bakterije shigella |
| HRP20210243TT HRP20210243T1 (hr) | 2009-09-28 | 2021-02-11 | Hiperbulirajući sojevi bakterije shigella |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170845TT HRP20170845T1 (hr) | 2009-09-28 | 2017-06-02 | Hiperbulirajući sojevi bakterije shigella |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20130052227A1 (hr) |
| EP (2) | EP2483389B1 (hr) |
| JP (3) | JP2013505716A (hr) |
| KR (1) | KR101786025B1 (hr) |
| CN (2) | CN102906245B (hr) |
| AU (1) | AU2010299577B2 (hr) |
| BR (1) | BR112012006912A8 (hr) |
| CA (1) | CA2775642C (hr) |
| CY (2) | CY1118970T1 (hr) |
| DK (2) | DK2483389T3 (hr) |
| ES (2) | ES2632747T3 (hr) |
| GB (1) | GB0917002D0 (hr) |
| HR (2) | HRP20170845T1 (hr) |
| HU (1) | HUE053188T2 (hr) |
| LT (2) | LT2483389T (hr) |
| NZ (1) | NZ599598A (hr) |
| PL (2) | PL2483389T3 (hr) |
| PT (2) | PT3279313T (hr) |
| SI (2) | SI2483389T1 (hr) |
| WO (1) | WO2011036564A2 (hr) |
| ZA (1) | ZA201202934B (hr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8647642B2 (en) | 2008-09-18 | 2014-02-11 | Aviex Technologies, Llc | Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment |
| GB201017519D0 (en) | 2010-10-15 | 2010-12-01 | Novartis Vaccines Inst For Global Health S R L | Vaccines |
| US9636390B2 (en) | 2012-11-19 | 2017-05-02 | Indian Council Of Medical Research | Immunogenic antigens of shigella |
| WO2014076714A2 (en) * | 2012-11-19 | 2014-05-22 | Indian Council Of Medical Research | Novel immunogenic antigens of shigella |
| EA033538B1 (ru) | 2013-03-15 | 2019-10-31 | Univ Arkansas | Композиции и способы усиления иммунного ответа на кишечные патогены |
| EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
| CN104974946B (zh) * | 2014-04-08 | 2019-01-11 | 中国科学院天津工业生物技术研究所 | 耐高渗透压的重组大肠杆菌及其应用 |
| CL2014001126A1 (es) * | 2014-04-29 | 2014-08-29 | Univ Chile | Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec. |
| CN107921116A (zh) | 2015-06-16 | 2018-04-17 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
| CN105647893A (zh) * | 2016-03-04 | 2016-06-08 | 江南大学 | 一种D-丙氨酰-D-丙氨酸羧肽酶dacD基因及应用 |
| CN105647892A (zh) * | 2016-03-04 | 2016-06-08 | 江南大学 | 一种D-丙氨酰-D-丙氨酸羧肽酶dacA基因及应用 |
| AU2017260323B2 (en) | 2016-05-03 | 2023-11-16 | The Board Of Trustees Of The University Of Arkansas | Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same |
| WO2017218949A2 (en) * | 2016-06-17 | 2017-12-21 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| EP3263695A1 (en) | 2016-06-29 | 2018-01-03 | GlaxoSmithKline Biologicals SA | Immunogenic compositions |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| WO2019163785A1 (ja) * | 2018-02-20 | 2019-08-29 | 株式会社山田養蜂場本社 | 膜小胞組成物の製造方法 |
| JP7242829B2 (ja) * | 2018-07-24 | 2023-03-20 | ワッカー ケミー アクチエンゲゼルシャフト | 新規細菌ｌｐｐ突然変異体及び組換えタンパク質の分泌産生のためのその使用 |
| CN111363018B (zh) * | 2020-03-26 | 2021-10-01 | 廊坊梅花生物技术开发有限公司 | 重组菌株及其在l-色氨酸制备中的应用 |
| EP4262804A2 (en) * | 2020-12-18 | 2023-10-25 | Codexis, Inc. | Engineered uridine phosphorylase variant enzymes |
| GB202112149D0 (en) | 2021-08-24 | 2021-10-06 | Glaxosmithkline Biologicals Sa | Shigellla vaccine |
| CN113897324B (zh) * | 2021-10-13 | 2023-07-28 | 云南师范大学 | 一种用作抗锰剂的JcVIPP1重组大肠杆菌及其构建方法 |
| GB202118913D0 (en) | 2021-12-23 | 2022-02-09 | Glaxosmithkline Biologicals Sa | Method for preparing outer membrane vesicles |
| CN116855471B (zh) * | 2023-09-04 | 2023-11-28 | 江苏申基生物科技有限公司 | 一种嘌呤核苷磷酸化酶突变体及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| NZ230423A (en) | 1988-08-25 | 1993-08-26 | Liposome Co Inc | A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| NZ253137A (en) | 1992-06-25 | 1996-08-27 | Smithkline Beecham Biolog | Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a. |
| CZ289476B6 (cs) | 1993-03-23 | 2002-01-16 | Smithkline Beecham Biologicals (S.A.) | Očkovací přípravek a způsob jeho výroby |
| WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US5681736A (en) | 1994-10-05 | 1997-10-28 | Antex Biologics, Inc. | Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| US6887483B2 (en) * | 1995-12-01 | 2005-05-03 | University Of Iowa Research Foundation | Non-toxic mutants of pathogenic gram-negative bacteria |
| EP2172216A3 (en) | 1997-03-10 | 2010-11-24 | Ottawa Hospital Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| JP4426091B2 (ja) | 1997-09-05 | 2010-03-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニンを含有する水中油型エマルション |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| IL137809A0 (en) | 1998-02-12 | 2001-10-31 | American Cyanamid Co | Pneumococcal and meningococcal vaccines formulated with interleukin-12 |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| AU1431101A (en) * | 1999-10-04 | 2001-05-10 | University Of Maryland Biotechnology Institute | Novel adjuvant comprising a lipopolysaccharide antagonist |
| US20010044416A1 (en) | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
| KR100894767B1 (ko) | 2000-09-26 | 2009-04-24 | 이데라 파마슈티칼즈, 인코포레이티드 | 화학적인 위치 변화에 의해 면역자극 올리고누클레오티드유사체의 면역자극 활성을 조절하는 방법 |
| GB0103171D0 (en) * | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| CA2493977A1 (en) | 2002-08-02 | 2004-02-19 | Glaxosmithkline Biologicals Sa | Vaccine composition comprising lipooligosaccharide with reduced phase variability |
| DE602004029657D1 (de) | 2003-03-24 | 2010-12-02 | Intercell Ag | Verbesserte impfstoffe |
| KR101143060B1 (ko) | 2004-04-05 | 2012-05-08 | 화이자 프로덕츠 인코포레이티드 | 미세유체화된 수중유 유화액 및 백신 조성물 |
| US8062644B2 (en) | 2005-02-18 | 2011-11-22 | Novartis Vaccines & Diagnostics Srl. | Immunogens from uropathogenic Escherichia coli |
| AU2012207041A1 (en) | 2005-02-18 | 2012-08-16 | J. Craig Venter Institute, Inc. | Proteins and nucleic acids from meningitis/sepsis-associated Escherichia Coli |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
-
2009
- 2009-09-28 GB GBGB0917002.8A patent/GB0917002D0/en not_active Ceased
-
2010
- 2010-09-28 DK DK10768559.6T patent/DK2483389T3/en active
- 2010-09-28 WO PCT/IB2010/002582 patent/WO2011036564A2/en active Application Filing
- 2010-09-28 BR BR112012006912A patent/BR112012006912A8/pt not_active Application Discontinuation
- 2010-09-28 JP JP2012530359A patent/JP2013505716A/ja active Pending
- 2010-09-28 PL PL10768559T patent/PL2483389T3/pl unknown
- 2010-09-28 US US13/498,723 patent/US20130052227A1/en not_active Abandoned
- 2010-09-28 EP EP10768559.6A patent/EP2483389B1/en active Active
- 2010-09-28 HU HUE17168855A patent/HUE053188T2/hu unknown
- 2010-09-28 DK DK17168855.9T patent/DK3279313T3/da active
- 2010-09-28 AU AU2010299577A patent/AU2010299577B2/en active Active
- 2010-09-28 CN CN201080052643.0A patent/CN102906245B/zh active Active
- 2010-09-28 PT PT171688559T patent/PT3279313T/pt unknown
- 2010-09-28 SI SI201031507T patent/SI2483389T1/sl unknown
- 2010-09-28 NZ NZ599598A patent/NZ599598A/xx not_active IP Right Cessation
- 2010-09-28 CN CN201710653787.5A patent/CN107475168A/zh active Pending
- 2010-09-28 LT LTEP10768559.6T patent/LT2483389T/lt unknown
- 2010-09-28 SI SI201032053T patent/SI3279313T1/sl unknown
- 2010-09-28 ES ES10768559.6T patent/ES2632747T3/es active Active
- 2010-09-28 KR KR1020127011091A patent/KR101786025B1/ko active IP Right Grant
- 2010-09-28 CA CA2775642A patent/CA2775642C/en active Active
- 2010-09-28 PT PT107685596T patent/PT2483389T/pt unknown
- 2010-09-28 ES ES17168855T patent/ES2846901T3/es active Active
- 2010-09-28 LT LTEP17168855.9T patent/LT3279313T/lt unknown
- 2010-09-28 PL PL17168855T patent/PL3279313T3/pl unknown
- 2010-09-28 EP EP17168855.9A patent/EP3279313B1/en active Active
-
2012
- 2012-04-20 ZA ZA2012/02934A patent/ZA201202934B/en unknown
-
2016
- 2016-03-15 JP JP2016050789A patent/JP2016105736A/ja active Pending
- 2016-04-08 US US15/094,077 patent/US11339367B2/en active Active
-
2017
- 2017-06-02 HR HRP20170845TT patent/HRP20170845T1/hr unknown
- 2017-06-16 CY CY20171100637T patent/CY1118970T1/el unknown
-
2019
- 2019-02-08 JP JP2019021756A patent/JP7023248B2/ja active Active
-
2021
- 2021-02-04 CY CY20211100093T patent/CY1123774T1/el unknown
- 2021-02-11 HR HRP20210243TT patent/HRP20210243T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210243T1 (hr) | Hiperbulirajući sojevi bakterije shigella | |
| NZ627915A (en) | Probiotic derived non-viable material for infection prevention and treatment | |
| RU2606022C2 (ru) | Способ получения капсульного полисахарида с пневмококковым серотипом | |
| EA201270173A1 (ru) | Получение полиовируса с высокими титрами для получения вакцины | |
| RU2014143979A (ru) | Пригодные для использования в пищу бактерии lactobacillus rhamnosus | |
| DK1201749T3 (da) | Fremgangsmåde til fremstilling af humane bruskimplantater ved hjælp af in vitro dyrkede chondrocytter | |
| WO2015052350A3 (en) | Live attenuated vaccines | |
| EA201070870A1 (ru) | Композиция, содержащая белок и диспергированный жир | |
| WO2009103065A3 (en) | Compositions and methods for production of biofuels | |
| EP3321358A3 (en) | Rotavirus-like particle production in plants | |
| WO2014154787A3 (fr) | Procédé d'enrichissement en protéines de la biomasse de microalgues | |
| MY166220A (en) | Rabies virus like particle production in plants | |
| ZA202306500B (en) | Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins | |
| JP2010148517A5 (hr) | ||
| WO2017213469A3 (ko) | 남조류 스피룰리나 추출물을 함유하는 세포 배양액, 이의 제조방법, 및 이를 이용한 세포의 배양방법 | |
| SG10201810846WA (en) | Cold-adapted-viral-attenuation (cava) and novel attenuated poliovirus strains | |
| WO2019204494A3 (en) | Date palm medium compositions and methods | |
| WO2008066774A3 (en) | INTERFERON-β PRODUCTION MODULATING LISTERIA STRAINS AND METHODS FOR USING SAME | |
| CN102839157A (zh) | 稳定共表达hST3GalIV和β1-4GalT1的MDCK细胞系及构建方法和应用 | |
| Superti et al. | HT-29 cells: a new substrate for rotavirus growth | |
| PL430205A1 (pl) | Szczepionka, sposób przygotowania szczepionki oraz sposób biotyzacji borówki amerykańskiej | |
| CN105543123A (zh) | 一株生产抗氧化肽的苏云金芽孢杆菌及其筛选方法 | |
| WO2013093512A3 (en) | Vaccine - screening method | |
| Hirayama et al. | Megalochelys: gigantic tortoise from the Neogene of Myanmar | |
| TW200700019A (en) | Smell-free algal extract and method for producing the same |